A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center

Leukemia Research

Volumn 31, Issue 6, 2007, Pages 765-771

  Xin, Li ^a   Wan jun, Sun ^b   Zeng jun, Li ^a   Yao zhong, Zhao ^a   Yun tao, Li ^a   Yan, Li ^a   Chang chun, Wan ^a   Qiao chuan, Li ^a   Ren chi, Yang ^a   Ming zhe, Han ^a   Jian xiang, Wang ^a   Lu gui, Qiu ^a  

^a Blood Diseases Hospital   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Acute promyelocytic leukemia; As2O3; ATRA; Chemotherapy; Long term survival; Prognostic factors

Indexed keywords

ANTILEUKEMIC AGENT; ARSENIC TRIOXIDE; HUANGDAIPIAN; LACTATE DEHYDROGENASE; RETINOIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY; CHINESE MEDICINE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; FUSION GENE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SEX; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; OXIDES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRETINOIN;

EID: 34249902546     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.028     Document Type: Article

References (30)

1. Tallman M.S., Anderson J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American intergroup protocol. Blood 100 (2002) 4298-4302
2. Castaiqne S., Chomienne C., Daniel M.T., Ballerini P., Berqer R., Fenaux P., et al. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia I. Clinical results. Blood 76 (1990) 1704-1709
3. Tallman M.S., Anderson J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337 (1997) 1021-1028
4. Fenaux B.P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94 (1999) 1192-1200
5. Sanz M.A., Fenaux P., Lo Coco F., and European APL Group of Experts. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica 90 (2005) 1231-1235
6. Sanz M.A., Lo Coco F., Martin G., Avvisati G., Rayon C., Barbui T., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96 (2000) 1247-1253
7. Mandelli F., Latagliata R., Avvisati G., Fazi P., Rodeghiero F., Leoni F., et al. Treatment of elderly patients (> or + 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17 (2003) 1085-1090
8. Asou N., Adachi K., Tamura J., Kanamaru A., Kaqevama S., Hiraoka A., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 16 (1998) 78-85
9. Sanz M.A., Martin G., Rayon C., Esteve J., Gonzalez M., Diaz-Mediavilla J., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia. Blood 94 (1999) 3015-3021
10. Goldberg M.A., Ginsburq D., Mayer R.J., Stone R.M., Maquire M., Rosenthal D.S., et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?. Blood 69 (1987) 187-191
11. Cunninqham I., Gee T.S., Reich L.M., Kempin S.J., Naval A.N., and Clarkson B.D. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73 (1989) 1116-1122
12. Rodeghiero F., Avvisati G., Castaman G., Barbui T., and Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 75 (1990) 2112-2117
13. Zhang T.D., and Li Y.S. Treatment of acute granulocytic leukemia with "Ai Ling No 1". Clinical analysis and experimental research. Chin J Integrated Tradit West Med 4 (1984) 19-20
14. Li Y.S., Zhang T.D., Li C.W., Zhao X.L., Wei Z.R., Tan W., et al. Traditional Chinese and Western medicine in the treatment of 27 patients with malignant lymphoma. Chin J Oncol 10 (1988) 61-62
15. Sun H.D., Ma L., Hu X.C., and Zhang T.D. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrated Tradit West Med 12 (1992) 170-171
16. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88 (1996) 1052-1061
17. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukemia. Br J Haematol 33 (1976) 451-458
18. Sanz M.A., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103 (2004) 1237-1243
19. Burnett A.K., Grimwade D., Solomon E., Wheatley K., and Goldstone A.H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial. Blood 93 (1999) 4131-4143
20. Fenaux P., Chastang G., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94 (1999) 1192-1200
21. Asou N., Kanamaru A., Miyawaki S., Ohtake S., and Tomonaga M. The JALSG APL92 study for newly diagnosed acute promyelocytic leukemia (APL): analysis of prognostic factors to increase cure rate in the next study. Blood 94 (Suppl.) (1999) 2262
22. Chou W.C., Tang J.L., Yao M., Liang Y.J., Lee F.Y., Lin M.T., et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia 11 (1997) 921-928
23. Lo Coco F., Nervi C., Avvisati G., and Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 12 (1998) 1866-1880
24. 3: an experience of 120 patients at a single institution. Int J of Hematol 70 (1999) 248-260
25. Sun G.L., Huang Y.G., Chang X.E., Jiang G.S., and Zhang T. Clinical study of treatment in 544 cases of acute promyelocytic leukemia with all-trans-retinoic acid. Chin J Hematol 13 (1992) 135-137
26. Wu X., Wang X., Qian X., Liu H., Ying J., Yang Z., et al. Four years'experience with the treatment of all-trans-retinoic acid in acute promyelocytic leukemia. Am J Hematol 43 (1993) 183-189
27. Fenaux P., Wattel E., Archimbaud E., Sanz M., Hecquet B., Fegueux N., et al. Prolonged follow-up confirms that all-trans-retinoic acid (ATRA) followed by chemotherapy reduces the risk of relapse in newly diagnosed acute promyelocytic leukemia (APL). Blood 84 (1994) 666-667
28. Lo Coco F., Diverio D., Avvisati G., Petti M.C., Meloni G., Pogliani E.M., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94 (1999) 2225-2229
29. Lo Coco F., Diverio D., Falini B., Biondi A., Nervi C., and Pelicci P.G. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94 (1999) 12-22
30. Zhang P., Wang S., Hu L., Qiu F., Yang H., Xiao Y., et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases. Clin J Hematol 21 (2000) 67-70